The reason the authorization process takes so long is probably related to the cost of the drug.
"Onyx announced the price of Kyprolis (carfilzomib) on 20 July 2012. The drug will cost $10,000 per 28-day cycle at the recommended dose for a patient of average size.
At that price and based on FDA-approved dosing schedules, Kyprolis will be the most expensive drug approved in the U.S. for multiple myeloma.
In comparison, Velcade costs between $4,000 to $8,000 per 28-day period, depending on the frequency of dosing, and Revlimid costs $7,900 per 28-day period at the FDA-approved 21-out-of-28-day dosing." From: http://www.myelomabeacon.com/news/2012/07/20/fda-approves-kyprolis-carfilzomib-for-relapsed-and-refractory-multiple-myeloma/
Things may be looking up for me if I don't have a heart attack from it !